ondansetron has been researched along with Arrhythmia in 17 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the risk of cardiac arrhythmias associated with ondansetron administration in the context of recent recommendations for identification of high-risk individuals." | 8.90 | Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. ( Finkelstein, Y; Freedman, SB; Rumantir, M; Uleryk, E, 2014) |
| "Ondansetron is a 5-HT₃ receptor antagonist commonly used as an antiemetic to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or postoperatively." | 8.89 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. ( Doggrell, SA; Hancox, JC, 2013) |
| "To explore the risk of cardiac arrhythmias associated with ondansetron administration in the context of recent recommendations for identification of high-risk individuals." | 4.90 | Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. ( Finkelstein, Y; Freedman, SB; Rumantir, M; Uleryk, E, 2014) |
| "Ondansetron is a 5-HT₃ receptor antagonist commonly used as an antiemetic to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or postoperatively." | 4.89 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. ( Doggrell, SA; Hancox, JC, 2013) |
| "A wide variety of bradyarrhythmias and tachyarrhythmias occur following ingestion." | 2.45 | Management of yellow oleander poisoning. ( Rajapakse, S, 2009) |
| " Statistical analysis of dose-response showed the maximum mean difference in QTcF, compared to placebo and corrected for baseline (ddQTcF), was less than 10 milliseconds (ms) after an 8 mg IV dose and approximately 20 ms after the 32 mg dose, each infused over 15 minutes." | 1.40 | Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study. ( Fang, L; Haberer, LJ; Hunt, TL; Ridgway, D; Russo, MW; Zuo, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, L | 1 |
| Sun, H | 1 |
| Al-Khalil, M | 1 |
| Sack, A | 1 |
| Elson, R | 1 |
| Pleat, J | 1 |
| Wang, EHZ | 1 |
| Sunderland, S | 1 |
| Edwards, NY | 1 |
| Chima, NS | 1 |
| Yarnold, CH | 1 |
| Schwarz, SKW | 1 |
| Coley, MA | 1 |
| Freedman, SB | 2 |
| Finkelstein, Y | 2 |
| Gummin, DD | 1 |
| Moeller, JR | 1 |
| Drendel, AL | 1 |
| Frommeyer, G | 2 |
| Fischer, C | 2 |
| Ellermann, C | 2 |
| Dechering, DG | 2 |
| Kochhäuser, S | 2 |
| Lange, PS | 2 |
| Wasmer, K | 1 |
| Fehr, M | 2 |
| Eckardt, L | 2 |
| Darpo, B | 1 |
| Benson, C | 1 |
| Brown, R | 1 |
| Dota, C | 1 |
| Ferber, G | 1 |
| Ferry, J | 1 |
| Jarugula, V | 1 |
| Keirns, J | 1 |
| Ortemann-Renon, C | 1 |
| Pham, T | 1 |
| Riley, S | 1 |
| Sarapa, N | 1 |
| Ticktin, M | 1 |
| Zareba, W | 1 |
| Couderc, JP | 1 |
| Doggrell, SA | 1 |
| Hancox, JC | 1 |
| Patel, J | 1 |
| Uleryk, E | 1 |
| Rumantir, M | 1 |
| Lee, JH | 1 |
| Park, YH | 1 |
| Kim, JT | 1 |
| Kim, CS | 1 |
| Kim, HS | 1 |
| Zuo, P | 1 |
| Haberer, LJ | 1 |
| Fang, L | 1 |
| Hunt, TL | 1 |
| Ridgway, D | 1 |
| Russo, MW | 1 |
| Tricco, AC | 1 |
| Soobiah, C | 1 |
| Hui, W | 1 |
| Antony, J | 1 |
| Struchkov, V | 1 |
| Hutton, B | 1 |
| Hemmelgarn, B | 1 |
| Moher, D | 1 |
| Straus, SE | 1 |
| Rajapakse, S | 1 |
| Miller, DR | 1 |
| Baguley, WA | 1 |
| Hay, WT | 1 |
| Mackie, KP | 1 |
| Cheney, FW | 1 |
| Cullen, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blinded, Randomized Control Trial of Prophylactic Ondansetron in a Post-operative Cardiac Surgery Population for Post-operative Nausea and Vomiting[NCT02966041] | 186 participants (Actual) | Interventional | 2018-03-06 | Completed | |||
| Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery[NCT04853147] | Phase 3 | 1,154 participants (Actual) | Interventional | 2021-04-27 | Completed | ||
| Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis[NCT05716854] | Phase 1 | 44 participants (Actual) | Interventional | 2023-03-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ondansetron and Arrhythmia
| Article | Year |
|---|---|
Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Humans; Nausea; Ondansetron; Randomized Co | 2013 |
Droperidol- and ondansetron-induced life-threatening arrhythmias.
Topics: Aged; Antiemetics; Arrhythmias, Cardiac; Droperidol; Fatal Outcome; Female; Humans; Long QT Syndrome | 2013 |
Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis.
Topics: Antiemetics; Arrhythmias, Cardiac; Emergency Treatment; Humans; Monitoring, Physiologic; Ondansetron | 2014 |
Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiogr | 2015 |
Management of yellow oleander poisoning.
Topics: Antibodies, Blocking; Antidotes; Antiemetics; Arrhythmias, Cardiac; Blood Pressure; Charcoal; Digoxi | 2009 |
2 trials available for ondansetron and Arrhythmia
10 other studies available for ondansetron and Arrhythmia
| Article | Year |
|---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents; Arrhythmias, Cardiac; Burns; Comorbidity; Drug Int | 2020 |
Route of ondansetron administration and ventricular arrhythmias.
Topics: Antiemetics; Arrhythmias, Cardiac; Humans; Ondansetron; Risk | 2017 |
Reply.
Topics: Arrhythmias, Cardiac; Humans; Ondansetron | 2017 |
Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Domperidone; Drug Interactions; Erythromycin; Fema | 2018 |
The effect of sevoflurane and ondansetron on QT interval and transmural dispersion of repolarization in children.
Topics: Adolescent; Anesthetics, Inhalation; Antiemetics; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Co | 2014 |
Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Topics: Adolescent; Adult; Antiemetics; Arrhythmias, Cardiac; Computer Simulation; Cross-Over Studies; Dose- | 2014 |
Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone.
Topics: Animals; Antiemetics; Arrhythmias, Cardiac; Domperidone; Dose-Response Relationship, Drug; Female; O | 2017 |
Arrhythmogenic potential of antiemetics: perspectives on risk-benefits.
Topics: Antiemetics; Arrhythmias, Cardiac; Atrial Fibrillation; Droperidol; Electrocardiography; Humans; Ind | 2003 |
Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide.
Topics: Adult; Antiemetics; Arrhythmias, Cardiac; Female; Humans; Injections, Intravenous; Male; Metoclopram | 1997 |